Showing results (91-100 of 119) with videos related to
Sort By:
Pageof 12
The New England Journal of Medicine|October 2, 2004
Pure red-cell aplasia and epoetin therapyCharles L Bennett, Stefano Luminari, Allen R Nissenson, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 22, 2018
Anaplastic Lymphoma Kinase Mutation (<i>ALK</i> F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to AlectinibBenedito A Carneiro, Sahithi Pamarthy, Ami N Shah, et al.Journal for Immunotherapy of Cancer|November 3, 2022
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapyToni K Choueiri, Harriet Kluger, Saby George, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 10, 2009
Bladder cancer. Clinical practice guidelines in oncologyJames E Montie, Robert R Bahnson, Samuel M Cohen, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2024
Abiraterone, Olaparib, or Abiraterone + Olaparib in First-Line Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects (BRCAAway)Maha Hussain, Masha Kocherginsky, Neeraj Agarwal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2024
Efficacy and Safety of Denileukin Diftitox-Cxdl, an Improved Purity Formulation of Denileukin Diftitox, in Patients With Relapsed or Refractory Cutaneous T-Cell LymphomaFrancine M Foss, Youn H Kim, H Miles Prince, et al.JAMA|May 5, 2005
The Research on Adverse Drug Events and Reports (RADAR) projectCharles L Bennett, Jonathan R Nebeker, E Allison Lyons, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2009
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?Elizabeth A Richey, E Alison Lyons, Jonathan R Nebeker, et al.Journal for Immunotherapy of Cancer|July 11, 2023
Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancerSachin R Jhawar, Shang-Jui Wang, Aditya Thandoni, et al.Blood|August 16, 2005
Long-term outcome of individuals with pure red cell aplasia and antierythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) ProjectCharles L Bennett, Denis Cournoyer, Kenneth R Carson, et al.Pageof 12